Identification of mitoxantrone as a new inhibitor of ROS1 fusion protein in non-small cell lung cancer cells

Lian Xiang Luo; Xing Xing Fan; Ying Li; Xia Peng; Yin Chun Ji; Wendy Wen Luan Hsiao; Liang Liu; Elaine Lai Han Leung; Xiao Jun Yao

doi:10.1039/c6md00643d

Identification of mitoxantrone as a new inhibitor of ROS1 fusion protein in non-small cell lung cancer cells

Lian Xiang Luo
, Xing Xing Fan
, Ying Li
, Xia Peng
, Yin Chun Ji
, Wendy Wen Luan Hsiao
, Liang Liu
, Elaine Lai Han Leung
, Xiao Jun Yao

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

Mitoxantrone, an FDA-approved drug for multiple sclerosis and hormone refractory prostate cancer, is identified as a potent inhibitor of ROS1 fusion protein by in silico screening in non-small cell lung cancer cells. Mitoxantrone can suppress the phosphorylation of ROS1 and subsequently inhibit its downstream signaling pathway and thus induce cell apoptosis.

Original language	English (US)
Pages (from-to)	621-624
Number of pages	4
Journal	MedChemComm
Volume	8
Issue number	3
DOIs	https://doi.org/10.1039/c6md00643d
State	Published - 2017
Externally published	Yes

ASJC Scopus subject areas

Biochemistry
Molecular Medicine
Pharmacology
Pharmaceutical Science
Drug Discovery
Organic Chemistry

Access to Document

10.1039/c6md00643d

Cite this

@article{f58eb92c6f2a423eb7f8e08684e1f62b,

title = "Identification of mitoxantrone as a new inhibitor of ROS1 fusion protein in non-small cell lung cancer cells",

abstract = "Mitoxantrone, an FDA-approved drug for multiple sclerosis and hormone refractory prostate cancer, is identified as a potent inhibitor of ROS1 fusion protein by in silico screening in non-small cell lung cancer cells. Mitoxantrone can suppress the phosphorylation of ROS1 and subsequently inhibit its downstream signaling pathway and thus induce cell apoptosis.",

author = "Luo, \{Lian Xiang\} and Fan, \{Xing Xing\} and Ying Li and Xia Peng and Ji, \{Yin Chun\} and Hsiao, \{Wendy Wen Luan\} and Liang Liu and Leung, \{Elaine Lai Han\} and Yao, \{Xiao Jun\}",

note = "Publisher Copyright: {\textcopyright} The Royal Society of Chemistry.",

year = "2017",

doi = "10.1039/c6md00643d",

language = "English (US)",

volume = "8",

pages = "621--624",

journal = "MedChemComm",

issn = "2040-2503",

publisher = "Royal Society of Chemistry",

number = "3",

}

TY - JOUR

T1 - Identification of mitoxantrone as a new inhibitor of ROS1 fusion protein in non-small cell lung cancer cells

AU - Luo, Lian Xiang

AU - Fan, Xing Xing

AU - Li, Ying

AU - Peng, Xia

AU - Ji, Yin Chun

AU - Hsiao, Wendy Wen Luan

AU - Liu, Liang

AU - Leung, Elaine Lai Han

AU - Yao, Xiao Jun

PY - 2017

Y1 - 2017

N2 - Mitoxantrone, an FDA-approved drug for multiple sclerosis and hormone refractory prostate cancer, is identified as a potent inhibitor of ROS1 fusion protein by in silico screening in non-small cell lung cancer cells. Mitoxantrone can suppress the phosphorylation of ROS1 and subsequently inhibit its downstream signaling pathway and thus induce cell apoptosis.

AB - Mitoxantrone, an FDA-approved drug for multiple sclerosis and hormone refractory prostate cancer, is identified as a potent inhibitor of ROS1 fusion protein by in silico screening in non-small cell lung cancer cells. Mitoxantrone can suppress the phosphorylation of ROS1 and subsequently inhibit its downstream signaling pathway and thus induce cell apoptosis.

UR - https://www.scopus.com/pages/publications/85016102959

UR - https://www.scopus.com/pages/publications/85016102959#tab=citedBy

U2 - 10.1039/c6md00643d

DO - 10.1039/c6md00643d

M3 - Article

AN - SCOPUS:85016102959

SN - 2040-2503

VL - 8

SP - 621

EP - 624

JO - MedChemComm

JF - MedChemComm

IS - 3

ER -

Identification of mitoxantrone as a new inhibitor of ROS1 fusion protein in non-small cell lung cancer cells

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this